|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00701571 |
|
Date of registration:
|
17/06/2008 |
|
Primary sponsor: |
|
|
Public title:
|
Video/Audio Distraction Analgesia for Simulated Oncology Procedure Pain
|
|
Scientific title:
|
Video/Audio Distraction Analgesia for Simulated Oncology Procedure Pain |
|
Date of first enrolment:
|
September 2005 |
|
Target sample size:
|
180 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00701571 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Samuel R Sharar, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University of Washington |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- healthy men and women
- 18-21y, 40-60y, or older than 60y
Exclusion Criteria:
- a predisposition to motion sickness
- unusual sensitivity or lack of sensitivity to pain
- chronic pain
- peripheral neuropathy
- sensitive skin
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Pain
|
|
Intervention(s)
|
|
Procedure: Virtual Reality distraction
|
|
Primary Outcome(s)
|
|
To compare positional techniques and differing types of VR presentation (immersive vs. low tech). We will also compare age cohorts (18-21, 40-60, and older than 60 years).
[Time Frame: upon completion of data collection]
|
|
Secondary ID(s)
|
|
1R21CA107256-01A1
|
|
26745
|
|
P20-CA103728-04
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|